(IN BRIEF) In the Phase 3 IsKia trial presented at the American Society of Hematology (ASH) Annual Meeting, Sarclisa® (isatuximab)…
(IN BRIEF) Roche has announced promising results from the Phase III INAVO120 study, which evaluated inavolisib in combination with palbociclib…